Address: 50 Soldiers Field Place, Boston, MA 02135 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world.
Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry.
Back in 2004, I came to Zhangjiang to establish my own research office based on my time in the US, and Medicilon was born.
From that moment on, we have forged ahead with tireless determination to help Medicilon grow in the past 19 years.
Innovation is at the core of the pharmaceutical industry, while quality is the lifeline of new drug R&D. Despite the years passing by, our principle of “innovation-driven and quality first” has remained true in the heart of every Medicilon staff. We will continue to innovate our integrated solutions by continuously improving R&D efficiency and striving to provide comprehensive preclinical R&D to all new drug developers as we build Medicilon into a leading CRO.
I sincerely hope that Medicilon can assist more and more new drug developers through increased efficiency and lower costs, help every Medicilon staff achieve brilliant results, deliver satisfactory harvests to every investor, and proudly demonstrate the benefits of Chinese medical/biomedical research capabilities to the world.
Our Vision
To provide comprehensive preclinical research for pharmaceutical companies, research institutions, and all scientific researchers around the world, and promote new drug development as a preclinical R&D outsourcing service provider.
Our Mission
To deliver high quality, innovative and cost effective services for our customers.
Our Value
Focus on Innovation
We seek to establish long-term partnerships with our clients and suppliers by promoting the development of a positive community with shared interests. We serve as a bridge between the upstream and downstream parts of the industrial chain, and seek to develop both our organization and employees through excellent operating processes and standards.
Win-Win Collaboration
We seek long-term partnerships with our clients and suppliers by establishing a community of shared interests. We serve as a bridge between the upstream and downstream parts of the industrial chain, and we yearn for development of both the organization and our employees through sound operating standards.
Clients First
We aim to satisfy our clients by fully meeting their R&D goals and by exceeding their expectations. We seek to exceed client requirements regarding quality, speed, cost, compliance and intellectual property protection working with them as a key part of their team.
Dedication
Our team is dedicated to client delivery motivated by the prospect of both career and personal growth and development. We are respectful and cooperative, as these values are essential for a harmonious, productive work environment.
We are respectful and cooperative, as these values are essential for a harmonious, productive work environment.
Establish Medicilon New Drug Open Innovation Center
Medicilon (Hangzhou) grandly opened.
Medicilon (Baoshan) started construction.
The main structure of the expansion project of the drug R&D laboratory in the Medicilon Nanhui Park was fully capped.
Medicilon has established several innovation service platforms such as antibody drug discovery platform, cell & gene therapy drug R&D service platform.
Medicilon has successively won the "Top 20 Most Influential CXO Enterprises", "Top 100 Listed Companies on the Science and Technology Innovation Board in 2022", "Top 100 Shanghai Emerging Industry Enterprises in 2022", " 2022 Shanghai Top 100 Growth Enterprises", "Top 30 Value Listed Companies on the Science and Technology Innovation Board", "2022 China Biomedical Technology Innovation Value List 'Most Influential and Innovative CXO Enterprise'" and other honorary titles.
Include in the MSCI China A-Share Index
AI + Laboratory Cross-Industry Collaboration
Establish a new chemical high-activity laboratory, PROTAC in vitro R&D platform and microRNA drug synthesis platform
Build a large animal drug efficacy model platform,establish a new mouse model of Middle Cerebral Artery Occlusion (MCAO)
Innovate and develop RNA bioanalysis and detection platform, tumor immune preclinical research service platform, antibody-drug conjugate (ADC) preclinical service platform, and biotechnology drug non-human primate safety evaluation professional technical service platform
Immuno-oncology integrated solutions developed for oncolytic viruses, RNAi, CAR-T and vaccine research technologies.
PROTAC drug discovery technology platform established.
Chemical AI technology introduced.
Shanghai Nanhui Industrial Park opened.
QE-HF-X mass spectrometer introduced to the Drug Metabolism and Pharmacokinetic (DMPK) Department
DNA-encoded chemical library introduced.
cGMP-based API production line established, based on IND, to provide CDMO services.
Shanghai Medicilon Inc. listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
Stock Code: 688202
Fifteenth anniversary celebrated.
GLP and AAALAC review passed.
Chemical process test platform expanded
Bioanalysis platform established and expanded
Cardiac safety evaluation integrated solutions improved.
Preclinical cardiac safety evaluation research integrated solutions established.
Clinical BE bioanalysis platform established.
Inhalation and ophthalmic administration evaluation platform established.
Registration and declaration integrated solutions established.
Tumor center expanded.
Experimental high-throughput Biacore equipment introduced.
LC-MS/MS spectrometers introduced.
Recognized as a “Qualified Organization for Shanghai Academicians and Expert Workstations”
Preparation center microbial laboratory completed.
Preparation center GMP-based pilot-scale test plant completed.
Immuno-oncology integrated solutions established.
Bio-tech drug bioanalysis integrated solutions established.
Antibody Drug Conjugate (ADC) preclinical integrated solutions established.
Generic Drug Quality Consistency Evaluation Integrated Solutions established.
Triple Quad 6500 mass spectrometer introduced.
New IVIS Lumina III introduced.
Construction of a 10,000 m2 biological medicine (antibody) research laboratory is finished.
Medicilon Science and Technology Association established, and first congress convened.
Tenth anniversary celebrated.
Establishment of Shanghai Academicians and Experts Workstation approved.
Construction of a new laboratory, covering 10,000 square meters, is finished.
Isotope biomarker service expanded.
CFDA GLP review passed
New foreign drugs for domestic pharmaceutical companies introduced.
Three-party cooperation mode – involving a foreign company, Medicilon, and a domestic pharmaceutical company – established.
Official government approval for Medicilon to be the holding company of MPI Preclinical Research (Shanghai) LLC granted.
Complete IND filing materials provided, in accordance with CFDA and FDA standards.
New drug R&D three-party cooperation promotion completed.
New drug discovery project under the Twelfth Five-year Plan initiated.
FDA/CFDA GLP project review passed.
CFDA GLP certification passed
GLP safety evaluation service provided, in accordance with CFDA and FDA standards.
Integrated antibody R&D platform established.
Fortune Capital investment received.
CFDA GLP certification application filed.
AAALAC Accreditation completed, and compliance with GLP standards for preclinical animal experiments introduced.
Isotope experiment platform established.
Research preparation and quality monitoring platform launched.
Joint venture preclinical research service launched.
Preclinical animal experiment facilities certified by the Shanghai Laboratory Animal Science Association.
Non-primate experiment platform established.
Joint venture company with MPI Research established.
Construction of a new laboratory, covering 20,000 square meters, is finished.
Non-GLP pharmaceutical and toxicological research project conducted.
On-site CFDA review, regarding pharmacokinetics materials and their application, passed.
Preclinical monkey research facilities certified by the Shanghai Forestry Bureau.
First integrated new drug R&D service project launched.
GLP and AAALAC training started.
Structural biology platform established.
Construction of a new laboratory, covering 2,500 square meters, completed.
Animal experiment facilities certified by the Shanghai Municipality Science and Technology Commission.
Reviewed by the Shanghai Laboratory Animal Science Association.
Chemical synthesis FTE team established.
Registered in Shanghai
Chemical and biological analysis service introduced.
First LC/MS/MS" equipment introduced.
ABOUT
